The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males

David Andrew Tompkins, Michael T Smith, George Bigelow, Ruin Moaddel, Swarajya Lakshmi Vatem Venkata, Eric C Strain

Research output: Contribution to journalArticle

Abstract

OBJECTIVE:: Opioid-induced hyperalgesia (OIH), increased sensitivity to noxious stimuli after repeated opioid exposures, has been demonstrated in preclinical studies. However, there is no accepted, prospective model of OIH after repeated opioid exposures currently available in humans. This study assessed a potential prospective OIH model. METHODS:: Double-blind intramuscular injections of a short-acting opioid (alfentanil 15 mcg/kg; N=8) were compared to active placebo (diphenhydramine 25 mg; N=3) on cold and pressure pain testing and standard abuse liability measures in eight 10-hour sessions (1 injection/session) over 4 to 5 weeks in healthy, pain-free males. Decreases from session baseline pain threshold (PThr) and tolerance (PTol) were calculated to represent hyperalgesia, and were assessed both within and across sessions. RESULTS:: Mean decreases in cold PTol were seen in the alfentanil group at 180 minutes (-3.8 s, ±26.5) and 480 minutes (-1.63 s, ±31.5) after drug administration. There was a trend for differences between conditions on cold PThr hyperalgesia but not for pressure PThr. Alfentanil participants had greater mean ratings on Liking and High visual analog scales at peak effects (30 min), but these scores did not change across sessions. DISCUSSION:: Repeated alfentanil exposures over 4 to 5 weeks resulted in within session decreases in cold pain tolerance from baseline but these differences were not substantially different from diphenhydramine controls. The results did not support the phenomenon of OIH in this model, although definitive conclusions regarding the existence of OIH in humans likely requires a larger sample size or an alternative model.

Original languageEnglish (US)
Pages (from-to)36-45
Number of pages10
JournalClinical Journal of Pain
Volume30
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Alfentanil
Intramuscular Injections
Hyperalgesia
Opioid Analgesics
Pain
Pain Threshold
Diphenhydramine
Pressure
Visual Analog Scale
Sample Size
Placebos
Injections

Keywords

  • abuse liability
  • alfentanil
  • algometer
  • cold pressor
  • opioid-induced hyperalgesia

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males. / Tompkins, David Andrew; Smith, Michael T; Bigelow, George; Moaddel, Ruin; Venkata, Swarajya Lakshmi Vatem; Strain, Eric C.

In: Clinical Journal of Pain, Vol. 30, No. 1, 01.2014, p. 36-45.

Research output: Contribution to journalArticle

@article{5e6aa16f167a4c41bb08f4e08aa50196,
title = "The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males",
abstract = "OBJECTIVE:: Opioid-induced hyperalgesia (OIH), increased sensitivity to noxious stimuli after repeated opioid exposures, has been demonstrated in preclinical studies. However, there is no accepted, prospective model of OIH after repeated opioid exposures currently available in humans. This study assessed a potential prospective OIH model. METHODS:: Double-blind intramuscular injections of a short-acting opioid (alfentanil 15 mcg/kg; N=8) were compared to active placebo (diphenhydramine 25 mg; N=3) on cold and pressure pain testing and standard abuse liability measures in eight 10-hour sessions (1 injection/session) over 4 to 5 weeks in healthy, pain-free males. Decreases from session baseline pain threshold (PThr) and tolerance (PTol) were calculated to represent hyperalgesia, and were assessed both within and across sessions. RESULTS:: Mean decreases in cold PTol were seen in the alfentanil group at 180 minutes (-3.8 s, ±26.5) and 480 minutes (-1.63 s, ±31.5) after drug administration. There was a trend for differences between conditions on cold PThr hyperalgesia but not for pressure PThr. Alfentanil participants had greater mean ratings on Liking and High visual analog scales at peak effects (30 min), but these scores did not change across sessions. DISCUSSION:: Repeated alfentanil exposures over 4 to 5 weeks resulted in within session decreases in cold pain tolerance from baseline but these differences were not substantially different from diphenhydramine controls. The results did not support the phenomenon of OIH in this model, although definitive conclusions regarding the existence of OIH in humans likely requires a larger sample size or an alternative model.",
keywords = "abuse liability, alfentanil, algometer, cold pressor, opioid-induced hyperalgesia",
author = "Tompkins, {David Andrew} and Smith, {Michael T} and George Bigelow and Ruin Moaddel and Venkata, {Swarajya Lakshmi Vatem} and Strain, {Eric C}",
year = "2014",
month = "1",
doi = "10.1097/AJP.0b013e3182851758",
language = "English (US)",
volume = "30",
pages = "36--45",
journal = "Clinical Journal of Pain",
issn = "0749-8047",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The effect of repeated intramuscular alfentanil injections on experimental pain and abuse liability indices in healthy males

AU - Tompkins, David Andrew

AU - Smith, Michael T

AU - Bigelow, George

AU - Moaddel, Ruin

AU - Venkata, Swarajya Lakshmi Vatem

AU - Strain, Eric C

PY - 2014/1

Y1 - 2014/1

N2 - OBJECTIVE:: Opioid-induced hyperalgesia (OIH), increased sensitivity to noxious stimuli after repeated opioid exposures, has been demonstrated in preclinical studies. However, there is no accepted, prospective model of OIH after repeated opioid exposures currently available in humans. This study assessed a potential prospective OIH model. METHODS:: Double-blind intramuscular injections of a short-acting opioid (alfentanil 15 mcg/kg; N=8) were compared to active placebo (diphenhydramine 25 mg; N=3) on cold and pressure pain testing and standard abuse liability measures in eight 10-hour sessions (1 injection/session) over 4 to 5 weeks in healthy, pain-free males. Decreases from session baseline pain threshold (PThr) and tolerance (PTol) were calculated to represent hyperalgesia, and were assessed both within and across sessions. RESULTS:: Mean decreases in cold PTol were seen in the alfentanil group at 180 minutes (-3.8 s, ±26.5) and 480 minutes (-1.63 s, ±31.5) after drug administration. There was a trend for differences between conditions on cold PThr hyperalgesia but not for pressure PThr. Alfentanil participants had greater mean ratings on Liking and High visual analog scales at peak effects (30 min), but these scores did not change across sessions. DISCUSSION:: Repeated alfentanil exposures over 4 to 5 weeks resulted in within session decreases in cold pain tolerance from baseline but these differences were not substantially different from diphenhydramine controls. The results did not support the phenomenon of OIH in this model, although definitive conclusions regarding the existence of OIH in humans likely requires a larger sample size or an alternative model.

AB - OBJECTIVE:: Opioid-induced hyperalgesia (OIH), increased sensitivity to noxious stimuli after repeated opioid exposures, has been demonstrated in preclinical studies. However, there is no accepted, prospective model of OIH after repeated opioid exposures currently available in humans. This study assessed a potential prospective OIH model. METHODS:: Double-blind intramuscular injections of a short-acting opioid (alfentanil 15 mcg/kg; N=8) were compared to active placebo (diphenhydramine 25 mg; N=3) on cold and pressure pain testing and standard abuse liability measures in eight 10-hour sessions (1 injection/session) over 4 to 5 weeks in healthy, pain-free males. Decreases from session baseline pain threshold (PThr) and tolerance (PTol) were calculated to represent hyperalgesia, and were assessed both within and across sessions. RESULTS:: Mean decreases in cold PTol were seen in the alfentanil group at 180 minutes (-3.8 s, ±26.5) and 480 minutes (-1.63 s, ±31.5) after drug administration. There was a trend for differences between conditions on cold PThr hyperalgesia but not for pressure PThr. Alfentanil participants had greater mean ratings on Liking and High visual analog scales at peak effects (30 min), but these scores did not change across sessions. DISCUSSION:: Repeated alfentanil exposures over 4 to 5 weeks resulted in within session decreases in cold pain tolerance from baseline but these differences were not substantially different from diphenhydramine controls. The results did not support the phenomenon of OIH in this model, although definitive conclusions regarding the existence of OIH in humans likely requires a larger sample size or an alternative model.

KW - abuse liability

KW - alfentanil

KW - algometer

KW - cold pressor

KW - opioid-induced hyperalgesia

UR - http://www.scopus.com/inward/record.url?scp=84890432716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890432716&partnerID=8YFLogxK

U2 - 10.1097/AJP.0b013e3182851758

DO - 10.1097/AJP.0b013e3182851758

M3 - Article

C2 - 23446076

AN - SCOPUS:84890432716

VL - 30

SP - 36

EP - 45

JO - Clinical Journal of Pain

JF - Clinical Journal of Pain

SN - 0749-8047

IS - 1

ER -